

References

I-150

1. Darzalex (daratumumab) injection. [prescribing information] Janssen Biotech, Inc., Horsham, PA 2015. Revised 06/2019.
2. Sanchez L, Wang Y, Siegel D, Wang M. Daratumumab: A first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma. *Journal of Hematology & Oncology*. 2016;9(1):51. Available from: MEDLINE Complete, Ipswich, MA.
3. Naymagon L, Abdul-Hay M. Novel agents in the treatment of multiple myeloma: A review about the future. *Journal of Hematology & Oncology*. 2016;9(1):52. Available from: MEDLINE Complete, Ipswich, MA.
4. Bhatnagar V, Gormley N, Luo L, et al. FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy. *The Oncologist*. 2017;22:1347-1353.
5. Sanchez L, Wang Y, Siegel D, & Wang M. Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma. *Journal of Hematology & Oncology*. 2016;9:5159.
6. Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. *N Engl J Med*. 2016; 375:754-766.
7. National Comprehensive Cancer Network (NCCN). 2021. Daratumumab. NCCN Drugs & Biologics Compendium.
8. Clinical Pharmacology™ Compendium 2021. Tampa FL: Gold Standard, Inc. Daratumumab
9. MICROMEDEX®SOLUTIONS Compendia. 2020. Daratumumab.
10. Mateos M, Dimopoulos M, Cavo M, et. al. Daratumumab Plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. *N Engl J Med*. 2018;378:518-528.
11. National Comprehensive Cancer Network (NCCN). Daratumumab and Hyaluronidase. NCCN Drugs and Biologics Compendium®. 2020.
12. DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj) injection. [prescribing information] Janssen Biotech, Inc., Horsham, PA 2015. 05/2020.
13. Darzalex (daratumumab), injection, for intravenous use [package insert]. Janssen Biotech. Horsham, PA. Revised 08/2020
14. Darzalex faspro (daratumumab and hyaluronidase-fihj), injection, for subcutaneous use [package insert]. Janssen Biotech. Horsham, PA. Revised 02/2021
15. Huang H, Zhu J, Yao M, et al. Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study. *Journal of hematology & oncology*. 2021;14(1):25.
16. Gordan L, Chang M, Lafeuille M-H, et al. Real-world utilization and safety of daratumumab IV rapid infusions administered in a community setting: A retrospective observational study. *Drugs - real world outcomes*. February 2021.

17. Clinical Pharmacology™ Compendium. 2021. Tampa FL: Gold Standard, Inc. Daratumumab hyaluronidase.